Results 91 to 100 of about 3,283 (198)

Early Versus Delayed Introduction of Faricimab for Initially Treatment-Naïve Diabetic Macular Edema: A Real-World Pilot Study

Journal of Clinical & Translational Ophthalmology
Background: Faricimab is one of the most potent anti-vascular endothelial growth factors used in the management of diabetic macular edema (DME). However, real-world benefits regarding its timing and efficacy are still being explored.
Tanya Gupta, Benjamin Setters, Lama Hanbali, Shruti Wadhwa, Michael W. Daniels, Wei Wang, Charles Barr, Melis Kabaalioglu Guner, SriniVas R. Sadda, Aditya Verma   +9 more
doaj   +1 more source

Safety profile of faricimab: a multi-source pharmacovigilance analysis using FAERS and JADER

BMC Pharmacology and Toxicology
Faricimab is a bispecific antibody targeting vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2), offering a novel therapeutic approach for ocular diseases. However, its long-term safety profile remains under evaluation.
Chuanya Liu, Shangze Li, Ziyi Wang, Zhifu Li, Z. Fang, Yuan Zhang, Yu Gao   +6 more
semanticscholar   +1 more source

Efficacy of intravitreal faricimab therapy for polypoidal choroidal vasculopathy: A systematic review and meta-analysis [PDF]

Polypoidal choroidal vasculopathy (PCV) is an aneurismal type of macular neovascularization that show similarities with age-related macular degeneration and diseases that are part of the pachychoroid disease spectrum.
Grauslund, J., Grauslund, Jakob; id_orcid, Eriksen, Nathalie S., Arnold-Vangsted, Andreas, Balaratnasingam, Chandrakumar, Chhablani, Jay, Schneider, M., Subhi, Yousif, Subhi, Yousif; id_orcid, Grauslund, Jakob, Sabaner, M. Cem, Subhi, Y., Hajari, J.N., Chhablani, J., Sabaner, M.C., van Dijk, Elon H. C., Schou, M.G., Arnold-Vangsted, A., van Dijk, Elon H.C., Schneider, Miklos, Balaratnasingam, C., Cehofski, L.J., Hajari, Javad N., Eriksen, N.S., Dijk, E.H.C. van, Arnold‐Vangsted, Andreas, Schou, Marianne G., Cehofski, Lasse J.   +27 more
core   +1 more source

Progressive intraocular inflammation with anterior scleritis following intravitreal Faricimab for neovascular age-related macular degeneration: a case report

BMC Ophthalmology
Background To report a rare and instructive case of intraocular inflammation following intravitreal Faricimab (Vabysmo) injection that progressed to anterior scleritis despite early intervention. While Faricimab is widely used for neovascular age-related
Ching-Hua Hsu, Acer I-Hung Chen, Chien-Hsiung Lai, Nan-Ni Chen   +3 more
doaj   +1 more source

Safety Evaluation of Bilateral Same-Day Intravitreal Injection of Faricimab

Ophthalmology and Therapy
Introduction Intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents is the most commonly performed ophthalmic procedure. Many retinal specialists routinely perform same-day bilateral intravitreal anti-VEGF injections, in order to
Michael D. Karampelas, Irini P. Chatziralli, Dimitrios A. Karagiannis   +2 more
doaj   +1 more source

Short-term outcomes of treatment switch to faricimab in patients with aflibercept-resistant neovascular age-related macular degeneration

Graefe's Archive for Clinical and Experimental Ophthalmology
To report short-term outcomes of treatment switch to faricimab in real-world patients with aflibercept-resistant neovascular age-related macular degeneration (AMD).
Miklos Schneider, Jakob Bjerager, Delila Hodzic-Hadzibegovic, O. Klefter, Y. Subhi, J. Hajari   +5 more
semanticscholar   +1 more source

Human Factors Studies to Assess the Usability of the Faricimab Prefilled Syringe [PDF]

Mark R Barakat,1,2 Henry M Kwong Jr,2,3 Gelson Marcon,4 Olivia E O’Leary,4 Liliana P Paris,5 Petrick Schneider,4 Yannan Tang,5 Jordan M Graff2,6,7 1Retina Macula Institute of Arizona, Scottsdale, AZ, USA; 2Department of Ophthalmology, University of ...
Graff JM, O'Leary OE, Paris LP, Barakat MR, Schneider P, Kwong Jr HM, Marcon G, Tang Y   +7 more
core  

Real-World Efficacy of Intravitreal Faricimab for Diabetic Macular Edema:A Systematic Review [PDF]

Background: Diabetic macular edema (DME) is a prevalent exudative maculopathy, and anti-vascular endothelial growth factor (anti-VEGF) therapy is the first-line choice for treatment.
Vergmann, Anna Stage, Grauslund, Jakob; id_orcid, Yousif Subhi, Subhi, Yousif, Vergmann, Anna Stage; id_orcid, Subhi, Yousif; id_orcid, Nasimi, Safiullah, Safiullah Nasimi, Nasimi, Nasratullah, Grauslund, Jakob, Nasratullah Nasimi, Jakob Grauslund, Anna Stage Vergmann   +12 more
core   +1 more source

Functional Real-World Outcomes of Aflibercept 8 mg Versus Faricimab After Loading Phase in Diabetic Macular Edema

Ophthalmology and Therapy
Introduction Aflibercept 8 mg and faricimab provide effective anatomical and visual acuity improvements in diabetic macular edema (DME), although functional recovery may not be fully captured by conventional endpoints.
Feliciana Menna, Mattia Calabro, Antonio Guillot, Laura De Luca, Alessandro Meduri, Antonio Baldascino, Stefano Lupo, Enzo Maria Vingolo   +7 more
doaj   +1 more source

Efficacy of Faricimab in the Treatment of Diabetic Macular Edema and Faricimab-Related Changes in OCT and OCT Angiography

Our study aimed to assess the anatomical changes in the retina, including the assessment of the reduction of diabetic macular edema (DME) on optical coherence tomography (OCT) and the improvement of retinal microvascular parameters, defined by the ...
Dorota Wyględowska-Promieńska, Mariola Dorecka, Łukasz Drzyzga, Katarzyna Witek, Dorota Śpiewak   +4 more
core   +1 more source